

**PE/Texas Red® Anti-human CD14 Antibody
*61D3***Catalog number: 101411S0, 101411S1, 101411S2
Unit size: 25 tests, 100 tests, 500 tests**Product Details**

Storage Conditions	2-8°C with minimized light exposure. Do not freeze.
Expiration Date	12 months upon receiving
Concentration	0.1 mg/mL
Formulation	Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

Antibody Properties

Species Reactivity	Human
Class	Primary
Clonality	Monoclonal
Host	Mouse
Immunogen	CD14 (LPS-Receptor)
Clone	61D3
Conjugate	PE/Texas Red®

Biological Properties

Preparation	Antibody purified by affinity chromatography and then conjugated with PE/Texas Red® under optimal conditions
Application	Flow Cytometry (FACS)

Spectral Properties

Conjugate	PE/Texas Red®
Excitation Wavelength	567 nm
Emission Wavelength	615 nm

Applications

61D3 is an anti-human monoclonal antibody that targets the CD14 antigen. CD14 (sometimes referred to as myeloid cell-specific leucine-rich glycoprotein or LPS receptor) is a transmembrane protein that is located on the surface of cells such as macrophages. CD14 acts in critical cellular pathways, for example, the toll-like receptor signaling pathway, cell surface receptor signaling pathway and lipopolysaccharide-mediated signaling pathway. Moreover, in certain organisms, it promotes interleukin-8 secretion, is a positive regulator of tumor necrosis factor production and is a promoter of type I interferon production. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands like LY96. CD14 is a very popular antibody target, with over 42000 publications in the last decade. CD14 is essential for immunology, cell biology and neuroscience research, often serving as a phenotypic marker for differentiating cell types in flow

cytometric applications. This antibody was purified through affinity chromatography and conjugated to PE/Texas Red[®] (ex/em = 567/615 nm). It is compatible with the 561 nm laser and 615/20 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte Advanteon).